Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ultragenyx (NASDAQ:RARE) and G1 Therapeutics Inc (NASDAQ:GTHX).
Ultragenyx (RARE)
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Ultragenyx today and set a price target of $92. The company’s shares closed on Friday at $84.76, close to its 52-week high of $88.41.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 13.8% and a 63.2% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Rubius Therapeutics Inc, and Sarepta Therapeutics.
Currently, the analyst consensus on Ultragenyx is a Strong Buy with an average price target of $91.60.
See today’s analyst top recommended stocks >>
G1 Therapeutics Inc (GTHX)
BTIG analyst Dane Leone maintained a Buy rating on G1 Therapeutics Inc today and set a price target of $80. The company’s shares closed on Friday at $61.05, close to its 52-week high of $64.83.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 19.9% and a 66.0% success rate. Leone covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics Inc, Blueprint Medicines, and Bluebird Bio.
G1 Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $60.50, representing a -0.9% downside. In a report issued on September 6, H.C. Wainwright also maintained a Buy rating on the stock with a $61 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
